FLR insider notice: 55,178 common shares via Merrill Lynch (NYSE)
Rhea-AI Filing Summary
Fluor Corporation filed a Form 144 notifying a proposed Rule 144 sale of 55,178 common shares through Merrill Lynch (Dallas) with an aggregate market value of $3,440,85808/11/2025. The proposed sale represents roughly 0.034% of Fluor's 161,664,371 outstanding shares.
The filing lists the securities as originally acquired as restricted stock equity awards from Fluor on 02/23/2016 (5,178 shares) and 11/11/2022 (46,785 shares). It also states no securities were sold in the past three months and includes the seller's representation that they do not possess undisclosed material adverse information; no trading-plan adoption date is indicated on the form.
Positive
- Specified share count and value: 55,178 shares totaling $3,440,858, providing clear disclosure of the proposed sale size.
- No recent sales: Filing states "Nothing to Report" for securities sold during the past three months.
- Acquisition transparency: All reported shares were acquired as restricted stock equity awards with acquisition dates and amounts listed.
Negative
- No 10b5-1 plan date indicated: The form does not show a trading-plan adoption date or instruction date, leaving execution method unspecified.
- Proposed sale date present: An approximate sale date of 08/11/2025 is given, which may introduce timing uncertainty for investors tracking insider activity.
Insights
TL;DR: A routine insider sale notice for 55,178 shares (~0.034% of float), modest in scale and unlikely to move the market materially.
The Form 144 reports a proposed sale of 55,178 common shares through Merrill Lynch with an aggregate market value of $3.44M, scheduled approximately for 08/11/2025. Relative to the reported outstanding share count of 161,664,371, the package is very small (~0.034%), indicating limited dilution or supply pressure from this single filing. The securities were acquired as restricted stock awards in 2016 and 2022, and the filer reports no sales in the past three months, which reduces immediate execution uncertainty. The absence of a stated 10b5-1 plan adoption date on the form leaves the execution framework unspecified in the filing itself.
TL;DR: Disclosure follows Rule 144 format and includes required seller representations, but the filing does not specify a 10b5-1 plan date.
The document contains the standard representation that the seller does not possess undisclosed material adverse information and records the acquisition of shares via restricted equity awards (dates and amounts provided). It notes "Nothing to Report" for sales in the prior three months, which is consistent with a non-active seller. Material governance items are routine: the broker is identified and the exchange is NYSE. However, the form does not indicate a plan adoption or instruction date for any Rule 10b5-1 trading arrangement, which would otherwise provide stronger evidence of pre-planned disposal timing.